
FLGT — Fulgent Genetics Inc
NASDAQ · Healthcare · Diagnostics & Research
$19.77
+$0.18 (+0.92%)
Fulgent Genetics Inc (FLGT) is a diagnostics & research company listed on NASDAQ. It is led by Ming Hsieh, based in 4399 Santa Anita Avenue, El Monte, CA, United States, 91731, with about 1,313 employees. Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
Latest reported FLGT revenue for 2025-09-30 was $84.1M. Net income was -$6.8M. Revenue was up 2.8% from 2025-06-30 to 2025-09-30. FLGT currently screens at market cap $586.6M.
Use this FLGT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the FLGT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the FLGT SEC filings page. Lician reads the product cache first so this HTML stays unique to Fulgent Genetics Inc even when a live quote feed is slow.
About Fulgent Genetics Inc
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
FLGT Key Statistics
Market Cap
$586.65M
Volume
184,093
Previous Close
$19.45
Day Range
$19.35 – $20.06
EPS
$0.00
Revenue
$283.47M
Net Income
-$43.82M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-2.0%
Profit Margin
-15.5%
Employees
1,313
FLGT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $283.47M | $289.21M | $67.70M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$43.82M | -$175.24M | -$24.08M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 |
Total Assets
$1.22B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$55.14M
Operating Cash Flow
$21.06M
Free Cash Flow
$0.00
Fulgent Genetics Inc Company Information
- Chairman & CEO
- Ming Hsieh
- Headquarters
- 4399 Santa Anita Avenue, El Monte, CA, United States, 91731
- Website
- www.fulgentgenetics.com
- Phone
- 626 350 0537
- IPO / Founded
- 2016-09-29
- Sector
- Healthcare
- Industry
- Diagnostics & Research